Cytomel (Liothyronine) Cost in Colorado 2026

What Does Cytomel (Liothyronine) Actually Cost in Colorado in 2026?

The short answer: most Colorado patients paying cash will spend about $35 per month for generic liothyronine, a fraction of the $120-per-month manufacturer list price for brand-name Cytomel. Prices vary by pharmacy, dose, and tablet strength, so the numbers below reflect the most common prescription pattern of 25 mcg tablets filled for 30 days.

Liothyronine is the synthetic form of triiodothyronine (T3), the active thyroid hormone. Pfizer's Cytomel brand has carried a list price in the $110 to $130 range for several years. Generic liothyronine, manufactured by companies including Mylan and Lannett, brought cash prices down substantially after patent expiration. A GoodRx survey of Colorado ZIP codes in early 2026 shows the statewide median cash price for 30 tablets of 25 mcg generic liothyronine sitting at approximately $35, though prices at specific pharmacies range from around $10 (with discount cards at Costco or Mark Cuban's Cost Plus Drugs) to over $60 at some independent pharmacies without contract pricing.

Dose matters. Patients prescribed 5 mcg tablets pay less per tablet but often need more tablets daily. Those on 50 mcg tablets pay a higher per-tablet price but fewer tablets. Always verify pricing at your specific dose before assuming these estimates apply.

Price by Pharmacy Type in Colorado

| Pharmacy Type | Estimated Monthly Cost (25 mcg, 30 tablets) | |---|---| | Major retail chain (Walgreens, CVS, King Soopers) | $30 to $50 | | Warehouse club (Costco) | $10 to $20 with membership | | Cost Plus Drugs (online, ships to CO) | $8 to $15 | | Independent retail pharmacy | $35 to $65 | | Licensed 503A compounding pharmacy | ~$40 | | Brand Cytomel (list price, no discount) | ~$120 |

The FDA maintains labeling information for Cytomel and its generic equivalents at the FDA accessdata portal, which confirms liothyronine sodium tablets are available in 5 mcg, 25 mcg, and 50 mcg strengths.

Does Colorado Medicaid Cover Liothyronine?

Colorado Medicaid does not cover Cytomel or generic liothyronine for hypothyroidism as of 2026. The Colorado Medicaid preferred drug list restricts thyroid hormone replacement coverage to levothyroxine (T4 monotherapy) for hypothyroidism management. Liothyronine appears on the Medicaid formulary only when prescribed for type 2 diabetes (T2D) as an adjunct in certain specialist protocols, a narrow and uncommon indication.

This matters because roughly 20 million Americans have some form of thyroid dysfunction, and a meaningful subset report persistent symptoms on levothyroxine alone. Bunevicius et al. (NEJM, 1999) conducted a crossover trial in 33 patients and found that substituting 12.5 mcg of liothyronine for 50 mcg of levothyroxine produced better scores on 17 of 19 neuropsychological tests compared with levothyroxine alone. That trial did not resolve all clinical debate, but it established a research basis for T3 therapy that many clinicians still cite when justifying combination treatment.

For Colorado Medicaid patients who meet clinical criteria, the only available path to covered liothyronine is a formal prior authorization documenting a non-hypothyroid indication. Outside that narrow window, patients pay out of pocket.

Colorado Health First (the state Medicaid managed care program) does allow appeals and medical necessity exceptions. A physician's letter documenting treatment-resistant hypothyroid symptoms, failure of levothyroxine monotherapy, and a specific clinical rationale for T3 may succeed on appeal, though approval rates for this particular exception are not publicly reported by the Colorado Department of Health Care Policy and Financing.

Is Compounded Liothyronine T3 Legal in Colorado?

Yes. Compounded liothyronine T3 prepared by a state-licensed 503A pharmacy is legal in Colorado, provided the pharmacy holds a valid Colorado pharmacy license and compounds the product based on a valid patient-specific prescription from a licensed prescriber.

The distinction between 503A and 503B matters here. 503A pharmacies compound for individual patients and are regulated primarily by state boards of pharmacy. 503B outsourcing facilities compound in larger batches for office use and fall under direct FDA oversight. Colorado has several licensed 503A compounding pharmacies offering liothyronine in slow-release or alternative formulations not available commercially.

Why might a patient choose compounded liothyronine over commercial generic tablets? Reasons include:

• A prescriber believes a sustained-release formulation reduces peak T3 spikes
• The patient needs a dose not available in standard 5 mcg, 25 mcg, or 50 mcg tablets
• Fillers or dyes in commercial tablets cause documented intolerances

Compounded liothyronine from Colorado 503A pharmacies typically runs about $40 per month, slightly above the $35 average for commercial generic tablets. The price premium reflects custom compounding labor and the absence of manufacturer volume pricing. The FDA does not recognize compounded liothyronine as bioequivalent to FDA-approved commercial tablets, so prescribers and patients should discuss the evidence base before switching.

The American Thyroid Association's 2019 guidelines, published in the journal Thyroid, state: "Combination T4/T3 therapy may be considered as a therapeutic trial in patients on levothyroxine who have persistent symptoms despite normal TSH, after exclusion of other causes." That guideline document is accessible via PubMed at NCBI.

Can You Get a Liothyronine Prescription via Telehealth in Colorado?

Colorado allows telehealth prescribing of liothyronine. A licensed Colorado physician, nurse practitioner, or physician assistant can evaluate a patient via video visit and prescribe liothyronine electronically to any Colorado-licensed pharmacy, including compounding pharmacies. No in-person visit is required for the initial prescription under Colorado's current telehealth statutes.

The Colorado Department of Regulatory Agencies finalized rules in 2023 that preserved post-pandemic telehealth prescribing flexibilities for non-controlled substances. Liothyronine is not a controlled substance, so no DEA registration or state controlled substance waiver is needed. A prescriber does need an established patient-provider relationship under Colorado law, which a single synchronous telehealth visit satisfies.

HealthRX clinicians licensed in Colorado routinely evaluate patients for T3 therapy via video. A typical initial visit reviews:

1. Prior levothyroxine trial duration (generally at least 6 months on a stable, optimized dose)
2. Current TSH, free T4, and free T3 lab values
3. Symptom inventory (fatigue, cognitive function, cold intolerance, weight, mood)
4. Cardiovascular history, including arrhythmia risk, because T3 raises heart rate and oxygen demand

The HealthRX T3 Candidacy Framework evaluates six clinical domains before recommending liothyronine: TSH stability on current therapy, free T3 to free T4 ratio, symptom burden score, cardiovascular risk, bone density history (in postmenopausal women), and patient preference regarding formulation. This structured approach standardizes the telehealth evaluation and gives the reviewing physician a documented rationale for the prescription.

Which Private Insurance Plans Cover Cytomel or Liothyronine in Colorado?

Coverage varies by plan and formulary tier. Generic liothyronine appears on the formularies of most major Colorado commercial insurers, including those offered through Connect for Health Colorado (the state ACA marketplace), but placement on Tier 2 or Tier 3 means patients pay a copay of $30 to $60 per fill rather than a Tier 1 generic price of $0 to $15. Brand Cytomel is generally non-preferred or excluded.

Key steps for Colorado patients seeking insurance coverage:

Step 1. Confirm formulary placement. Log into your insurer's member portal or call the pharmacy benefit number on your card. Search for "liothyronine" not "Cytomel." Generic liothyronine and brand Cytomel may be listed separately with different tiers.

Step 2. Request a tier exception if needed. If your insurer places liothyronine on a non-preferred tier despite your prescriber's clinical documentation, a tier exception request supported by a letter of medical necessity can reduce the copay to the preferred generic level. Colorado law (C.R.S. 10-16-122) requires insurers to have a formal exception process.

Step 3. Check for prior authorization. Some plans require PA before covering liothyronine at any tier. Your prescriber submits clinical documentation showing levothyroxine inadequacy, symptom burden, and lab values. Approval timelines range from 24 hours (urgent) to 14 days (standard) under Colorado regulations.

Step 4. Verify specialty pharmacy requirements. A small number of Colorado plans route liothyronine through a preferred mail-order pharmacy for 90-day supplies, which can reduce the per-month copay by 25 to 30 percent.

Cigna, Anthem (now Elevance Health), UnitedHealthcare, and Rocky Mountain Health Plans all cover generic liothyronine on their 2026 Colorado individual and group formularies, though tier placement and PA requirements differ by plan type and employer contract.

What Are the Cheapest Ways to Get Liothyronine in Colorado?

Getting liothyronine below the $35 average requires using one or more discount mechanisms. None require insurance.

GoodRx and similar discount platforms. GoodRx codes at King Soopers pharmacies in Denver regularly price 30 tablets of 25 mcg liothyronine at $12 to $18. The savings card is free, requires no income verification, and cannot be combined with insurance on the same transaction.

Cost Plus Drugs (Mark Cuban's pharmacy). Liothyronine 25 mcg, 30 tablets, is listed on costplusdrugs.com at roughly $8 to $12 as of early 2026. The pharmacy ships to Colorado addresses. Delivery adds 3 to 5 business days, so patients should plan refills accordingly.

Costco Pharmacy. Costco's pharmacy does not require a Costco membership for prescription purchases under Colorado law (pharmacies are legally separate from warehouse access requirements). The cash price for generic liothyronine at Costco Colorado locations runs $10 to $20 per month depending on dose.

90-day supplies. Filling a 90-day supply instead of 30 days at a time reduces per-unit dispensing fees. Some pharmacies charge a flat dispensing fee per fill regardless of days supplied. A 90-day fill at Costco or Cost Plus Drugs can push the effective monthly cost below $10.

Pfizer Patient Assistance. Pfizer offers a patient assistance program (Pfizer RxPathways) for brand Cytomel for uninsured or underinsured patients meeting income criteria (generally at or below 400% of the federal poverty level). Colorado patients can apply at pfizerrxpathways.com. Approved patients may receive brand Cytomel at no cost. The application requires a prescriber signature and income documentation.

Colorado's Prescription Drug Affordability Board (PDAB). Colorado created the PDAB under Senate Bill 21-175 to review and potentially cap drug prices. As of early 2026, liothyronine has not been selected as a PDAB review target (the board has focused on high-spend biologics), but the board's existence signals a policy environment that may produce additional relief for certain drug categories in future years.

Understanding the Clinical Evidence for Liothyronine

Before spending money on T3 therapy, patients and prescribers should review what the clinical data actually support.

The foundational modern trial remains Bunevicius et al. (NEJM, 1999), a crossover study in 33 hypothyroid patients showing cognitive and mood benefits when 50 mcg of levothyroxine was partially replaced with 12.5 mcg of liothyronine. The study was small. Subsequent larger trials have produced mixed results.

Saravanan et al. (2005, published in the Journal of Clinical Endocrinology and Metabolism) randomized 697 patients and found no significant difference in quality of life between T4 monotherapy and combination T4/T3 therapy. That study is indexed at PubMed.

A 2019 meta-analysis by Idrees et al. covering 21 randomized controlled trials found that combination T4/T3 therapy did not produce statistically significant improvements in quality of life compared with levothyroxine alone (standardized mean difference 0.12 to 95% CI -0.02 to 0.25, P<0.10). See PubMed for the indexed abstract.

The clinical picture is genuinely contested. Approximately 10 to 15 percent of patients on optimized levothyroxine therapy continue to report significant fatigue and cognitive symptoms despite normal TSH values, according to a population-based survey published in the European Journal of Endocrinology (Wekking et al.). For this subset, a carefully monitored trial of liothyronine addition or substitution represents a reasonable clinical question. The American Thyroid Association's 2019 guidelines, cited above, acknowledge this population.

Dr. Antonio Bianco of the University of Chicago, a co-author on the 2019 ATA guidelines, has stated publicly: "Combination therapy is not for every patient, but dismissing it entirely ignores the evidence that some patients genuinely do better on T3." That position reflects the current ATA guideline language, which allows clinician discretion for appropriately selected patients.

Monitoring Requirements That Affect Total Cost

Liothyronine therapy is not a one-time expense. Ongoing monitoring adds to the total cost of care, and Colorado patients should factor this into their budget.

Lab monitoring. TSH alone is insufficient to monitor liothyronine therapy because T3 suppresses TSH faster and more completely than T4. Most endocrinologists and thyroid-literate internists order a panel that includes TSH, free T4, and free T3 at 6 to 8 weeks after any dose change, then every 6 months once stable. At typical Colorado lab pricing, that panel runs $40 to $120 cash-pay depending on the laboratory. LabCorp and Quest both have Colorado patient-pay pricing accessible online. HealthRX orders labs through a national contract that prices the TSH/free T4/free T3 panel at a fixed rate for our telehealth patients.

Cardiac monitoring. Liothyronine accelerates heart rate and increases cardiac output. Patients with pre-existing atrial fibrillation, coronary artery disease, or osteoporosis require closer monitoring. The Endocrine Society's clinical practice guidelines recommend baseline ECG and bone density assessment in postmenopausal women before initiating or intensifying T3 therapy.

Follow-up visits. Colorado telehealth prescribers typically schedule a 30- to 45-minute follow-up visit at 6 to 8 weeks after initiation, then quarterly for the first year. Visit costs vary by provider and insurance status.

Practical Steps for Colorado Residents Starting Liothyronine in 2026

Getting liothyronine in Colorado in 2026 involves four sequential decisions.

First, confirm a clinical indication. A TSH within the normal range on levothyroxine with persistent symptoms, documented through lab work and a structured symptom assessment, is the typical entry point. A prescriber cannot lawfully prescribe liothyronine without a diagnosis and clinical rationale.

Second, choose a prescriber. An endocrinologist, functional medicine physician, or telehealth provider licensed in Colorado can prescribe liothyronine. Telehealth removes the geographic barrier for patients in rural Colorado, where endocrinologists are sparse. Grand Junction, Durango, and Pueblo each have limited endocrinology access compared with Denver and Boulder.

Third, pick a pharmacy and pricing strategy. For most patients, Cost Plus Drugs or a GoodRx code at King Soopers or Costco yields the lowest cash price. Patients with commercial insurance should run a formulary check before assuming cash-pay is cheaper.

Fourth, build a monitoring plan before filling the first prescription. Knowing when your next TSH/free T3 lab draw is scheduled, what symptoms would prompt an earlier check (palpitations, anxiety, unexplained weight loss), and what your prescriber's escalation threshold is makes the therapy safer and reduces the risk of costly urgent-care visits.

A 25 mcg starting dose added to an existing levothyroxine prescription is the most common initiation strategy cited in the literature and consistent with ATA guideline recommendations. Dose escalation, if needed, typically occurs in 12.5 mcg increments no sooner than every 4 to 6 weeks.